406 CDX527–01, a phase 1 dose-escalation and expansion study of the PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies

• Laura Vitale,
• Michael Yellin,
• Li-Zhen He,
• Lawrence Thomas,
• Tracey Rawls,
• Diane Young,
• Philip Golden

Affiliations

Laura Vitale

Aff3 grid.417695.8Celldex Therapeutics, Inc. Charlottesville VA USA

Michael Yellin

Aff3 grid.417695.8Celldex Therapeutics, Inc. Charlottesville VA USA

Li-Zhen He

Aff663 grid.417695.8Celldex Therapeutics Hampton NJ USA

Lawrence Thomas

Aff2 grid.417695.8Celldex Therapeutics, Inc. Needham MA USA

Tracey Rawls

Celldex Therapeutics, Hampton, NJ, USA

Diane Young

Celldex Therapeutics, Hampton, NJ, USA

Philip Golden

Celldex Therapeutics, Hampton, NJ, USA